One of the more spurious and naive arguments proffered by the industry's antagonists and even some people in government is that the pricing of new treatments should reflect whether public funding contributed in any way to its development. …
Latest Video
Georgia Forrest
New Stories
-
New digital health reforms to give Australians a more complete medicines history
January 28, 2026 - - Latest News -
Peer-reviewed validation strengthens Paradigm’s osteoarthritis program
January 28, 2026 - - Australian Biotech -
Obesity medicines, the limits of the PBS, and the test of policy imagination
January 28, 2026 - - Latest News -
Patrys completes Reliis acquisition, expands clinical pipeline and strengthens board
January 28, 2026 - - Australian Biotech -
Trump administration launches third round of price negotiations, including the first renegotiation
January 28, 2026 - - Latest News -
UK life sciences report highlights pressures familiar to Australian industry
January 27, 2026 - - Latest News -
Americans pay a much lower share of health costs than we do in Australia
January 27, 2026 - - Latest News